Results 151 to 160 of about 18,617,874 (263)
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease +20 more
wiley +1 more source
Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio +15 more
wiley +1 more source
Objective Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life‐threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult‐onset Still's disease [AOSD]).
Alexei Grom +21 more
wiley +1 more source
Graphical Abstract Objective To evaluate the impact of bimekizumab, a dual interleukin (IL)‐17A and IL‐17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non‐radiographic axSpA [nr‐axSpA]) and 2 (radiographic axSpA [r ...
Walter P. Maksymowych +10 more
wiley +1 more source
Graphical Abstract Objective This study aimed to characterize whole blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or B lymphocyte stimulator/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to nonresponse. Methods Whole blood RNA sequencing was performed
Aimen Ibrahim +9 more
wiley +1 more source
Objective In APEX, guselkumab, which binds to the IL‐23p19 subunit and CD64 on IL‐23‐producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. Methods The APEX modified full analysis set included 1020 biologic‐
Christopher T. Ritchlin +12 more
wiley +1 more source
The roles of expectation, comparator, administration route, and population in open-label placebo effects: a network meta-analysis. [PDF]
Buergler S, Sezer D, Gaab J, Locher C.
europepmc +1 more source
Spatial Proteomics Identifies Distinct Synovial Microenvironments in Hip and Knee Osteoarthritis
Objective Osteoarthritis (OA) is a heterogeneous joint disease, yet mechanistic insights derive predominantly from knee OA and are often extrapolated to other joints. We investigated joint‐associated differences in the spatial molecular organization of hip and knee OA synovium.
Peng Xie +9 more
wiley +1 more source
A randomized trial that compared brain activity, efficacy and plausibility of open-label placebo treatment and cognitive repappraisal for reducing emotional distress. [PDF]
Schienle A, Kogler W, Wabnegger A.
europepmc +1 more source

